Yu-Waye Chu insider trades: CytomX Therapeutics (CTMX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Yu-Waye reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 18, 2025 | CTMX | ↓ Sell | 4,025 | $0.60 | $2K | Direct | Mar 20, 2025 (2d) |
| Apr 18, 2023 | FATE | ↓ Sell | 2,532 | $6.57 | $17K | Direct | Apr 19, 2023 (1d) |
| Jan 10, 2023 | FATE | ↓ Sell | 7,825 | $5.24 | $41K | Direct | Jan 11, 2023 (1d) |
| Apr 19, 2022 | FATE | ↓ Sell | 4,062 | $35.37 | $144K | Direct | Apr 21, 2022 (2d) |
| Jan 11, 2022 | FATE | ↓ Sell | 3,965 | $48.51 | $192K | Direct | Jan 13, 2022 (2d) |
| Dec 10, 2021 | FATE | ↓ Sell | 7,500 | $51.46 | $386K | Direct | Dec 13, 2021 (3d) |
| Apr 16, 2021 | FATE | ↓ Sell | 3,275 | $83.30 | $273K | Direct | Apr 20, 2021 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CTMX insiders
Open-market trades in the last 12 months
About Yu-Waye Chu's insider trades
Yu-Waye Chu is Chief Medical Officer at CytomX Therapeutics (CTMX). Since Apr 16, 2021, Yu-Waye has reported no open-market purchases and 7 sales worth $1.1M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (8 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CTMX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.